Dexmedetomidine and Bupivacaine With Bupivacaine in Ultrasonography Guided Fascia Iliaca Compartment Block in Adults
NCT ID: NCT02658760
Last Updated: 2016-10-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
60 participants
INTERVENTIONAL
2015-06-30
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fascia Iliaca Block Versus Intravenous Dexmedetomidine and Ketamine for Positioning Fracture Femur
NCT05705726
Dexmedetomidine Addition to Fascia Iliaca Compartment Block
NCT01600027
Fascia Iliaca Compartment Block for Proximal-end Femur Fractures
NCT02696915
Effect of Dexmedetomidine and Bupivacaine for Paravertebral Block
NCT02801188
Ultrasound-Guided Fascia Iliaca Compartmental Block Versus Spinal Anesthesia in Femoral Thrombectomy
NCT06745986
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bupivacaine
30cc of 0.25% bupivacaine
Bupivacaine
dexmedetomidine and Bupivacaine
Dexmedetomidine and bupivacaine
30cc of 0.25% bupivacaine and 2mg/kg dexmedetomidine
Dexmedetomidine
dexmedetomidine plus placebo
Bupivacaine
dexmedetomidine and Bupivacaine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dexmedetomidine
dexmedetomidine plus placebo
Bupivacaine
dexmedetomidine and Bupivacaine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Neurological diseases
* Coagulation abnormalities
* Infection at the site of block
14 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hamidreza Mahboobi
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hamidreza Mahboobi
Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nasim Abdi
Role: PRINCIPAL_INVESTIGATOR
Hormozgan University of Medical Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shahid Mohammadi hospital
Bandar Abbas, Hormozgan, Iran
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Hums.Rec.1394.74
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.